Revenue: As of FY2025 Q2, the actual value is USD 460.93 K.EPS: As of FY2025 Q2, the actual value is USD -0.014.<h3>Direct Sales</h3><ul><li>Revenue: $31,337 for the three months ended June 30, 2025, a decrease of 91% from $357,013 in 2024.</li><li>Cost of Sales: $1,199 for 2025, a decrease of 96% from $27,033 in 2024.</li><li>Operating Expenses: $462,531 for 2025, compared to $417,513 in 2024.</li><li>Loss from Operations: - $432,394 for 2025, compared to - $87,533 in 2024.</li></ul><h3>Pharmacy</h3><ul><li>Revenue: $26,441 for the three months ended June 30, 2025, a decrease of 90% from $256,713 in 2024.</li><li>Cost of Sales: $17,574 for 2025, a decrease of 76% from $71,919 in 2024.</li><li>Operating Expenses: $71,155 for 2025, compared to $108,194 in 2024.</li><li>Loss from Operations: - $62,228 for 2025, compared to $76,600 in 2024.</li></ul><h3>Hotel</h3><ul><li>Revenue: $112,377 for the three months ended June 30, 2025, a decrease of 6% from $120,097 in 2024.</li><li>Operating Costs: $254,383 for 2025, a decrease of 30% from $364,110 in 2024.</li><li>Operating Expenses: $89,202 for 2025, compared to $84,830 in 2024.</li><li>Loss from Operations: - $231,207 for 2025, compared to - $328,843 in 2024.</li></ul><h3>Manufacture and Sale</h3><ul><li>Revenue: $290,774 for the three months ended June 30, 2025, a decrease of 51% from $598,827 in 2024.</li><li>Cost of Sales: $271,902 for 2025, a decrease of 29% from $381,137 in 2024.</li><li>Operating Expenses: $103,607 for 2025, compared to $146,739 in 2024.</li><li>Loss from Operations: - $84,735 for 2025, compared to $70,951 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $1,150,477 for the six months ended June 30, 2025, compared to - $348,330 in 2024.</li><li>Net Cash Used in Investing Activities: - $11,227 for 2025, compared to - $239,967 in 2024.</li><li>Net Cash Provided by Financing Activities: $1,128,327 for 2025, compared to $796,550 in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to gain positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products. Additionally, it aims to raise cash through loans from related parties and potential equity offerings.</li><li>Non-Core Business: The company intends to explore opportunities in the healthcare market in China, including expanding its product line, acquiring additional pharmacies, and potentially operating nursing homes and clinics.</li></ul>

AiXin Life International, Inc. | 10-Q: FY2025 Q2 Revenue: USD 460.93 K